Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer
Background and Aim Evidence has emerged that a pretreatment immune profile in rectal cancer is associated with response to chemoradiotherapy (CRT) and recurrence after CRT. However, few studies have evaluated the immune profile differences after CRT regarding recurrence and nonrecurrence. Methods We...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2022-03, Vol.37 (3), p.542-550 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 550 |
|---|---|
| container_issue | 3 |
| container_start_page | 542 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 37 |
| creator | Hong, Seung Wook Lee, Seohyun Kim, Yun Jae Ahn, Soyeon Park, In Ja Hong, Seung‐Mo Hwang, Sung Wook Park, Sang Hyoung Yang, Dong‐Hoon Ye, Byong Duk Byeon, Jeong‐Sik Yang, Suk‐Kyun Kim, Jaeil Kim, Sang‐Yeob Myung, Seung‐Jae |
| description | Background and Aim
Evidence has emerged that a pretreatment immune profile in rectal cancer is associated with response to chemoradiotherapy (CRT) and recurrence after CRT. However, few studies have evaluated the immune profile differences after CRT regarding recurrence and nonrecurrence.
Methods
We included patients with advanced rectal cancer treated with CRT and surgery with recurrence within 1 year in a recurrence group. After sex and age matching with the recurrence group, patients with no recurrence for 3 years after CRT were included in a nonrecurrence group. We extracted the immune profile, including CD3 and CD8, from the surgical specimen after CRT using multispectral fluorescence immunohistochemistry and compared the two groups.
Results
The immune profiles of 65 patients with rectal cancer were assessed; 30 were included in the recurrence group and 35 were included in the nonrecurrence group. CD3+ and CD8+ T lymphocyte densities were significantly higher in the nonrecurrence group than in the recurrence group (CD3+; P |
| doi_str_mv | 10.1111/jgh.15773 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618237473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618237473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-216426c23a7624cd3f4b6923cbbdf589fe3247a2848ad75ece8ba68d1b4b9c2d3</originalsourceid><addsrcrecordid>eNp10T1PwzAQBmALgWj5GPgDyBILDCn-ShyPCEFbVIkF5shxLtRVEhc7Uem_x6XAgISXG-7RK98dQheUTGh8t6u35YSmUvIDNKZCkIRKkR2iMclpmihO1QidhLAihAgi02M04kIprnI-RmHetkMHeO1dbRvA5Ra3Q9PbdQMfUGG767qlDb0zS2hj9VusQ3DG6j72N7ZfYg9m8B46A1jXPXi8o87rKhrrOmy7Hel1g42OyJ-ho1o3Ac6_6yl6fXx4uZ8li-fp_P5ukRiecp4wmgmWGca1zJgwFa9FmSnGTVlWdZqrGjgTUrNc5LqSKRjIS53lFS1FqQyr-Cm63ufG4d4HCH0RBzDQNLoDN4SCZTRnXArJI736Q1du8F38XVRcEkUFU1Hd7JXxLgQPdbH2ttV-W1BS7C5RxEsUX5eI9vI7cShbqH7lz-ojuN2DTdz79v-k4mk620d-AgcvlMc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637091429</pqid></control><display><type>article</type><title>Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hong, Seung Wook ; Lee, Seohyun ; Kim, Yun Jae ; Ahn, Soyeon ; Park, In Ja ; Hong, Seung‐Mo ; Hwang, Sung Wook ; Park, Sang Hyoung ; Yang, Dong‐Hoon ; Ye, Byong Duk ; Byeon, Jeong‐Sik ; Yang, Suk‐Kyun ; Kim, Jaeil ; Kim, Sang‐Yeob ; Myung, Seung‐Jae</creator><creatorcontrib>Hong, Seung Wook ; Lee, Seohyun ; Kim, Yun Jae ; Ahn, Soyeon ; Park, In Ja ; Hong, Seung‐Mo ; Hwang, Sung Wook ; Park, Sang Hyoung ; Yang, Dong‐Hoon ; Ye, Byong Duk ; Byeon, Jeong‐Sik ; Yang, Suk‐Kyun ; Kim, Jaeil ; Kim, Sang‐Yeob ; Myung, Seung‐Jae</creatorcontrib><description>Background and Aim
Evidence has emerged that a pretreatment immune profile in rectal cancer is associated with response to chemoradiotherapy (CRT) and recurrence after CRT. However, few studies have evaluated the immune profile differences after CRT regarding recurrence and nonrecurrence.
Methods
We included patients with advanced rectal cancer treated with CRT and surgery with recurrence within 1 year in a recurrence group. After sex and age matching with the recurrence group, patients with no recurrence for 3 years after CRT were included in a nonrecurrence group. We extracted the immune profile, including CD3 and CD8, from the surgical specimen after CRT using multispectral fluorescence immunohistochemistry and compared the two groups.
Results
The immune profiles of 65 patients with rectal cancer were assessed; 30 were included in the recurrence group and 35 were included in the nonrecurrence group. CD3+ and CD8+ T lymphocyte densities were significantly higher in the nonrecurrence group than in the recurrence group (CD3+; P < 0.001, CD8+; P = 0.003) in the primary tumor. Consistent results were found in epithelial and stromal cells. Compared with the recurrence group, the distinct profiles of co‐expressed immune markers in the nonrecurrence group were revealed (CD3+CD8+, P = 0.001; CD3+CD8+PD‐L1−, P = 0.001; CD3+CD8+ FOXP3− PD‐L1−, P = 0.001).
Conclusions
Vigorous CD3+ and CD8+ T cell priming post‐CRT was prominent in the nonrecurrence group compared with that of the recurrence group. This finding suggests that differences in immune profiles may have clinical significance even after CRT.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.15773</identifier><identifier>PMID: 34993983</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Cancer ; CD3 antigen ; CD8 antigen ; Chemoradiotherapy ; Colorectal cancer ; Female ; Foxp3 protein ; Humans ; Immunohistochemistry ; Lymphocytes T ; Lymphocytes, tumor ; Male ; Neoplasm Recurrence, Local ; Patients ; PD-L1 protein ; Rectal neoplasms ; Rectal Neoplasms - metabolism ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Rectum ; Stromal cells ; Treatment Outcome ; Tumors</subject><ispartof>Journal of gastroenterology and hepatology, 2022-03, Vol.37 (3), p.542-550</ispartof><rights>2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-216426c23a7624cd3f4b6923cbbdf589fe3247a2848ad75ece8ba68d1b4b9c2d3</citedby><cites>FETCH-LOGICAL-c3533-216426c23a7624cd3f4b6923cbbdf589fe3247a2848ad75ece8ba68d1b4b9c2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.15773$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.15773$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34993983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hong, Seung Wook</creatorcontrib><creatorcontrib>Lee, Seohyun</creatorcontrib><creatorcontrib>Kim, Yun Jae</creatorcontrib><creatorcontrib>Ahn, Soyeon</creatorcontrib><creatorcontrib>Park, In Ja</creatorcontrib><creatorcontrib>Hong, Seung‐Mo</creatorcontrib><creatorcontrib>Hwang, Sung Wook</creatorcontrib><creatorcontrib>Park, Sang Hyoung</creatorcontrib><creatorcontrib>Yang, Dong‐Hoon</creatorcontrib><creatorcontrib>Ye, Byong Duk</creatorcontrib><creatorcontrib>Byeon, Jeong‐Sik</creatorcontrib><creatorcontrib>Yang, Suk‐Kyun</creatorcontrib><creatorcontrib>Kim, Jaeil</creatorcontrib><creatorcontrib>Kim, Sang‐Yeob</creatorcontrib><creatorcontrib>Myung, Seung‐Jae</creatorcontrib><title>Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aim
Evidence has emerged that a pretreatment immune profile in rectal cancer is associated with response to chemoradiotherapy (CRT) and recurrence after CRT. However, few studies have evaluated the immune profile differences after CRT regarding recurrence and nonrecurrence.
Methods
We included patients with advanced rectal cancer treated with CRT and surgery with recurrence within 1 year in a recurrence group. After sex and age matching with the recurrence group, patients with no recurrence for 3 years after CRT were included in a nonrecurrence group. We extracted the immune profile, including CD3 and CD8, from the surgical specimen after CRT using multispectral fluorescence immunohistochemistry and compared the two groups.
Results
The immune profiles of 65 patients with rectal cancer were assessed; 30 were included in the recurrence group and 35 were included in the nonrecurrence group. CD3+ and CD8+ T lymphocyte densities were significantly higher in the nonrecurrence group than in the recurrence group (CD3+; P < 0.001, CD8+; P = 0.003) in the primary tumor. Consistent results were found in epithelial and stromal cells. Compared with the recurrence group, the distinct profiles of co‐expressed immune markers in the nonrecurrence group were revealed (CD3+CD8+, P = 0.001; CD3+CD8+PD‐L1−, P = 0.001; CD3+CD8+ FOXP3− PD‐L1−, P = 0.001).
Conclusions
Vigorous CD3+ and CD8+ T cell priming post‐CRT was prominent in the nonrecurrence group compared with that of the recurrence group. This finding suggests that differences in immune profiles may have clinical significance even after CRT.</description><subject>Cancer</subject><subject>CD3 antigen</subject><subject>CD8 antigen</subject><subject>Chemoradiotherapy</subject><subject>Colorectal cancer</subject><subject>Female</subject><subject>Foxp3 protein</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, tumor</subject><subject>Male</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>Rectal neoplasms</subject><subject>Rectal Neoplasms - metabolism</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Rectum</subject><subject>Stromal cells</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10T1PwzAQBmALgWj5GPgDyBILDCn-ShyPCEFbVIkF5shxLtRVEhc7Uem_x6XAgISXG-7RK98dQheUTGh8t6u35YSmUvIDNKZCkIRKkR2iMclpmihO1QidhLAihAgi02M04kIprnI-RmHetkMHeO1dbRvA5Ra3Q9PbdQMfUGG767qlDb0zS2hj9VusQ3DG6j72N7ZfYg9m8B46A1jXPXi8o87rKhrrOmy7Hel1g42OyJ-ho1o3Ac6_6yl6fXx4uZ8li-fp_P5ukRiecp4wmgmWGca1zJgwFa9FmSnGTVlWdZqrGjgTUrNc5LqSKRjIS53lFS1FqQyr-Cm63ufG4d4HCH0RBzDQNLoDN4SCZTRnXArJI736Q1du8F38XVRcEkUFU1Hd7JXxLgQPdbH2ttV-W1BS7C5RxEsUX5eI9vI7cShbqH7lz-ojuN2DTdz79v-k4mk620d-AgcvlMc</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Hong, Seung Wook</creator><creator>Lee, Seohyun</creator><creator>Kim, Yun Jae</creator><creator>Ahn, Soyeon</creator><creator>Park, In Ja</creator><creator>Hong, Seung‐Mo</creator><creator>Hwang, Sung Wook</creator><creator>Park, Sang Hyoung</creator><creator>Yang, Dong‐Hoon</creator><creator>Ye, Byong Duk</creator><creator>Byeon, Jeong‐Sik</creator><creator>Yang, Suk‐Kyun</creator><creator>Kim, Jaeil</creator><creator>Kim, Sang‐Yeob</creator><creator>Myung, Seung‐Jae</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202203</creationdate><title>Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer</title><author>Hong, Seung Wook ; Lee, Seohyun ; Kim, Yun Jae ; Ahn, Soyeon ; Park, In Ja ; Hong, Seung‐Mo ; Hwang, Sung Wook ; Park, Sang Hyoung ; Yang, Dong‐Hoon ; Ye, Byong Duk ; Byeon, Jeong‐Sik ; Yang, Suk‐Kyun ; Kim, Jaeil ; Kim, Sang‐Yeob ; Myung, Seung‐Jae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-216426c23a7624cd3f4b6923cbbdf589fe3247a2848ad75ece8ba68d1b4b9c2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>CD3 antigen</topic><topic>CD8 antigen</topic><topic>Chemoradiotherapy</topic><topic>Colorectal cancer</topic><topic>Female</topic><topic>Foxp3 protein</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, tumor</topic><topic>Male</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>Rectal neoplasms</topic><topic>Rectal Neoplasms - metabolism</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Rectum</topic><topic>Stromal cells</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hong, Seung Wook</creatorcontrib><creatorcontrib>Lee, Seohyun</creatorcontrib><creatorcontrib>Kim, Yun Jae</creatorcontrib><creatorcontrib>Ahn, Soyeon</creatorcontrib><creatorcontrib>Park, In Ja</creatorcontrib><creatorcontrib>Hong, Seung‐Mo</creatorcontrib><creatorcontrib>Hwang, Sung Wook</creatorcontrib><creatorcontrib>Park, Sang Hyoung</creatorcontrib><creatorcontrib>Yang, Dong‐Hoon</creatorcontrib><creatorcontrib>Ye, Byong Duk</creatorcontrib><creatorcontrib>Byeon, Jeong‐Sik</creatorcontrib><creatorcontrib>Yang, Suk‐Kyun</creatorcontrib><creatorcontrib>Kim, Jaeil</creatorcontrib><creatorcontrib>Kim, Sang‐Yeob</creatorcontrib><creatorcontrib>Myung, Seung‐Jae</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hong, Seung Wook</au><au>Lee, Seohyun</au><au>Kim, Yun Jae</au><au>Ahn, Soyeon</au><au>Park, In Ja</au><au>Hong, Seung‐Mo</au><au>Hwang, Sung Wook</au><au>Park, Sang Hyoung</au><au>Yang, Dong‐Hoon</au><au>Ye, Byong Duk</au><au>Byeon, Jeong‐Sik</au><au>Yang, Suk‐Kyun</au><au>Kim, Jaeil</au><au>Kim, Sang‐Yeob</au><au>Myung, Seung‐Jae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>37</volume><issue>3</issue><spage>542</spage><epage>550</epage><pages>542-550</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
Evidence has emerged that a pretreatment immune profile in rectal cancer is associated with response to chemoradiotherapy (CRT) and recurrence after CRT. However, few studies have evaluated the immune profile differences after CRT regarding recurrence and nonrecurrence.
Methods
We included patients with advanced rectal cancer treated with CRT and surgery with recurrence within 1 year in a recurrence group. After sex and age matching with the recurrence group, patients with no recurrence for 3 years after CRT were included in a nonrecurrence group. We extracted the immune profile, including CD3 and CD8, from the surgical specimen after CRT using multispectral fluorescence immunohistochemistry and compared the two groups.
Results
The immune profiles of 65 patients with rectal cancer were assessed; 30 were included in the recurrence group and 35 were included in the nonrecurrence group. CD3+ and CD8+ T lymphocyte densities were significantly higher in the nonrecurrence group than in the recurrence group (CD3+; P < 0.001, CD8+; P = 0.003) in the primary tumor. Consistent results were found in epithelial and stromal cells. Compared with the recurrence group, the distinct profiles of co‐expressed immune markers in the nonrecurrence group were revealed (CD3+CD8+, P = 0.001; CD3+CD8+PD‐L1−, P = 0.001; CD3+CD8+ FOXP3− PD‐L1−, P = 0.001).
Conclusions
Vigorous CD3+ and CD8+ T cell priming post‐CRT was prominent in the nonrecurrence group compared with that of the recurrence group. This finding suggests that differences in immune profiles may have clinical significance even after CRT.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34993983</pmid><doi>10.1111/jgh.15773</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2022-03, Vol.37 (3), p.542-550 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618237473 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Cancer CD3 antigen CD8 antigen Chemoradiotherapy Colorectal cancer Female Foxp3 protein Humans Immunohistochemistry Lymphocytes T Lymphocytes, tumor Male Neoplasm Recurrence, Local Patients PD-L1 protein Rectal neoplasms Rectal Neoplasms - metabolism Rectal Neoplasms - pathology Rectal Neoplasms - therapy Rectum Stromal cells Treatment Outcome Tumors |
| title | Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T03%3A32%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20profile%20by%20multiplexed%20immunohistochemistry%20associated%20with%20recurrence%20after%20chemoradiation%20in%20rectal%20cancer&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Hong,%20Seung%20Wook&rft.date=2022-03&rft.volume=37&rft.issue=3&rft.spage=542&rft.epage=550&rft.pages=542-550&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.15773&rft_dat=%3Cproquest_cross%3E2618237473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637091429&rft_id=info:pmid/34993983&rfr_iscdi=true |